Ryvu Therapeutics

Ryvu Therapeutics is a clinical-stage drug discovery and development company focused on novel small molecule therapies that address emerging targets in oncology.

Ryvu Therapeutics was founded in 2007 and currently employs 230 scientists, including 80 Ph.Ds. Ryvu was previously known as Selvita, until renamed to Ryvu Therapeutics after spin out of the services segment.

The company is headquartered in Kraków, Poland. Ryvu Therapeutics is developing therapeutics that address clinical limitations of current treatments in oncology. Our work is defined by deep scientific knowledge, organizational efficiency, and a high throughput discovery engine platform.

Our lead candidate, RVU120, is a selective CDK8/CDK19 kinase inhibitor with potential for development in hematological malignancies and solid tumors, currently in Phase 1b study for the treatment of acute myeloid leukemia and myelodysplastic syndrome, and Phase I/II for the treatment of r/r metastatic or advanced solid tumors. SEL24 (MEN1703) is a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group, in Phase 2 clinical development for the treatment of acute myeloid leukemia.
Early pipeline candidates include candidates developed in the area of kinases, synthetic lethality and immuno-oncology.

Ryvu technological expertise is validated by global partnerships with BioNTech, Merck KGaA, Exelixis, Menarini Group and Leukemia & Lymphoma Society.